Table 3 SLMAP haplotype frequency and association with the risk of DR development in T2DM patients
Haplotypes | Non diabetic controls (NDC = 208) | T2DM patients without DR (DNR =320) | OR* (95%CI) P | T2DM patients with DR (N = 156) | OR8* (95% CI) P |
|---|---|---|---|---|---|
N (%) | N (%) | Controls vs T2DM | N (%) | DNR vs DR | |
T rs17058639C rs1043045G rs1057719 | 71 (34.14) | 129 (40.31) | Reference | 41 (26.28) | Reference |
C rs17058639T rs1043045A rs1057719 | 135 (64.90) | 188 (58.75) | 0.77 (0.53-1.10) 0.153 | 107 (68.59) | 1.79 (1.17-2.74) 0.007 |
C rs17058639C rs1043045G rs1057719 | 1 (0.48) | 2 (0.63) | 1.10 (0.10-12.35) 0.938 | 7 (4.49) | 11.01 (2.20-55.11) 0.004 |
C rs17058639C rs1043045A rs1057719 | 1 (0.48) | 0 | ND | 1 (0.64) | ND |
Grouped analysis | |||||
T rs17058639C rs1043045G rs1057719 | 71 (34.1) | 129 (40.4) | Reference | 41 (26.3) | Reference |
CTA + CCG + CCA | 137 (65.9) | 190 (59.6) | 0.76 (0.53-1.10) | 115 (73.7) | 1.90 (1.25-2.90) 0.003 |